Skip to main content
Figure 2 | Molecular Neurodegeneration

Figure 2

From: Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575

Figure 2

LY-411575 treatment had no effect on neuritic curvature in APPswe/PS1dE9xYFP mice when neurites up to 50 μm from the plaque border were analyzed. Data are representative of 44–138 neurites from 8–9 animals. The first imaging session (session 1) was acquired before the commencement of the treatment. Animals received daily gavage administrations of LY-411575 (5 mg-Kg) or vehicle and for the next 3 weeks and imaging sessions were completed on a weekly basis (sessions 2, 3 and 4). The curvature ratio of the same identified neurites were measured over time, with each neurite serving as its own control. No treatmentXsession effect was detected [F(3,561) = 0.171; P = 0.916] despite a slight trend towards a straightening effect observed in LY-411575 mice at the conclusion of the treatment.

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326